Caroline Seymour

Data from the phase 3 DESTINY-Breast06 trial were presented during the 2024 San Antonio Breast Cancer Symposium.

The anti-TIGIT therapy, vibostolimab, plus Keytruda and chemotherapy did not improve overall survival versus Tecentriq plus chemotherapy in extensive-stage small cell lung cancer.

Treatment with Cyramza plus Lonsurf did not improve overall survival compared with Lonsurf alone in heavily pretreated metastatic colorectal cancer.

Among patients with previously treated advanced clear cell renal cell carcinoma (RCC) Welireg continued to show some benefits, though not to overall survival.

Some patients with non-small cell lung cancer saw a 49% reduction in the risk of disease progression or death with ivonescimab versus Keytruda.

Patients with previously untreated locally advanced or metastatic urothelial carcinoma experienced favorable progression-free survival, overall survival and objective response rates when treated with Padcev and Keytruda versus chemotherapy.

Adding Imfinzi and Avastin to transarterial chemoembolization led to a 23% reduction in the risk of progression or death in patients with liver cancer.

Treatment with an all-oral regimen led to three-year overall survival and relapse-free survival rates of 97% in patients with acute promyelocytic leukemia, a subset of acute myeloid leukemia.

Opdivo and non–anthracycline containing chemotherapy before surgery produced promising pathologic complete response rates regardless of whether Opdivo was administered before or during treatment with carboplatin and paclitaxel in patients with stage 1 to 2B triple-negative breast cancer.

While CAR-T cell therapy is showing promise in treating patients with advanced renal cell carcinoma, there is still more research that needs to be done in this arena.

Patients with metastatic or recurrent head and neck squamous cell carcinoma had durable antitumor activity, according to findings from a phase 2 trial.

Patients with advanced non-small cell lung cancer with an EGFR mutation had a greater risk reduction for disease progression with frontline Rybrevant plus Leclaza compared with Tagrisso alone.

A 30% reduction in the risk of death versus. investigator’s choice of chemotherapy as second or third line therapy was concluded when Tivdak was combined for the treatment of recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.

The treatment combination of Rybrevant plus chemotherapy offers better progression-free survival for patients with advanced EGFR exon 20 insertion-positive NSCLC.

Elderly patients with acute myeloid leukemia did not experience a difference in relapse-free survival or non-relapse mortality with intensive versus non-intensive chemotherapy.

Immunotherapy combinations tended to improve outcomes for patients with metastatic kidney cancer who go on to receive surgery.

There was no major difference in progression-free survival between patients with relapsed/refractory chronic lymphocytic leukemia who were treated with Calquence or Brukinsa.

The addition of Tecentriq to platinum-based chemotherapy/gemcitabine did not boost outcomes in patients with metastatic bladder cancer, according to results from the IMvigor 140 trial.

Patients who underwent Revlimid, Velcade, and dexamethasone therapy followed by maintenance Revlimid, tended to have better outcomes when they underwent autologous stem cell transplant.

The investigational agent SOT101 was safe and tolerable when given alone and in combination with Keytruda for patients with solid tumors.

Adcetris plus doxorubicin, vinblastine and dacarbazine is the first regimen to improve overall survival compared to the current standard of care for patients with advanced-stage classical Hodgkin lymphoma.

Compared with Yervoy alone, the use of Yervoy plus Opdivo was associated with a significant survival benefit as a second-line treatment in patients with previously treated advanced melanoma, a type of skin cancer.

The use of Enhertu may also be beneficial across HER2-positive metastatic breast cancer subgroups including patients with and without brain metastases.

The average survival for patients with malignant pleural mesothelioma was less than a month after being diagnosed with COVID-19, according to a small study.

Fifteen percent of patients with myeloma did not have detectable antibodies two weeks after receiving the COVID-19 vaccine.

The data, according to an expert, show that treatment with Tecentriq could delay disease progression to an advanced stage, as well as the need for more aggressive therapy.

Treatment with sapanisertib was associated with limited activity and poor safety outcomes in patients with refractory metastatic renal cell carcinoma.

Premenopausal women with HR-positive, HER2-negative, lymph node-positive breast cancer and a risk for recurrence experienced benefits with chemotherapy plus endocrine therapy, with improvements in five-year invasive disease-free and overall survival.

An expert discusses genetic profiling and other advances in the treatment of colorectal cancer.

Splitting up Darzalex dosing had comparable results to standard dosing schedules in patients with myeloma.